4//SEC Filing
Harding Thomas C. 4
Accession 0000899243-22-027574
CIK 0001466301other
Filed
Aug 2, 8:00 PM ET
Accepted
Aug 3, 4:15 PM ET
Size
21.5 KB
Accession
0000899243-22-027574
Insider Transaction Report
Form 4
Harding Thomas C.
See Remarks
Transactions
- Sale
Common Stock
2022-08-02$1.46/sh−930$1,359→ 16,364 total - Exercise/Conversion
Common Stock
2022-08-01+1,563→ 16,283 total - Exercise/Conversion
Restricted Stock Units
2022-08-01−1,813→ 10,875 total→ Common Stock (1,813 underlying) - Exercise/Conversion
Common Stock
2022-08-01+1,813→ 17,294 total - Exercise/Conversion
Common Stock
2022-08-01+181→ 3,415 total(indirect: By Spouse) - Sale
Common Stock
2022-08-02$1.46/sh−802$1,172→ 15,481 total - Sale
Common Stock
2022-08-02$1.46/sh−77$112→ 3,338 total(indirect: By Spouse) - Exercise/Conversion
Restricted Stock Units
2022-08-01−1,563→ 3,125 total→ Common Stock (1,563 underlying) - Exercise/Conversion
Restricted Stock Units
2022-08-01−181→ 1,088 total(indirect: By Spouse)→ Common Stock (181 underlying)
Footnotes (7)
- [F1]Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- [F2]Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
- [F3]This transaction was executed in multiple trades at prices ranging from $1.4600 to $1.4957. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $1.4600 to $1.4923. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
- [F6]On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
- [F7]On January 31, 2020, the reporting person's wife was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Documents
Issuer
Clovis Oncology, Inc.
CIK 0001466301
Entity typeother
Related Parties
1- filerCIK 0001834833
Filing Metadata
- Form type
- 4
- Filed
- Aug 2, 8:00 PM ET
- Accepted
- Aug 3, 4:15 PM ET
- Size
- 21.5 KB